Covaxin gets nod for kids aged 2-18 years

The Subject Expert Committee (SEC) has given a nod for use of Covaxin for children in the 2-18 years age group

0
30
New Delhi: The Subject Expert Committee (SEC) of the drug regulator has recommended granting an emergency use authorisation to Bharat Biotech’s Covaxin for children aged between 2-18. The SEC has submitted its recommendation to the Drugs Controller General of India (DCGI) for final approval.
“After detailed deliberation, the committee recommended for grant of market authorization of the vaccine for the age group of 2 to 18 years for restricted use in an emergency situation,” the expert panel said in a statement.
It said that the emergency use authorisation, however, is subject to four conditions.
“The developer of Covaxin will continue the study as per Whole Virion, Inactivated Corona Virus Vaccine the approved clinical trial protocol,” SEC added.
Other conditions listed by the expert panel are: The firm should provide updated Prescribing Information/Package Insert (PI), Summary of Product Characteristics (SmPC) and Factsheet; the firm should submit safety data, including the data on AEFI and AESI, with due analysis, every 15 days for the first two months and monthly thereafter and also as per requirement of New Drugs & Clinical Trials Rules, 2019; and the firm should submit risk management plan.
Bharat Biotech had last week submitted Phase 2/3 clinical trials data of children’s trials to the DCGI for its verification and subsequent approval for emergency use authorisation (EUA) for the jab.
Two doses of Covaxin are likely to be administered to children with a gap of 28 days. For adults, the government has set a gap of 4-6 weeks between the two shots.
Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used on adults in India’s ongoing COVID-19 vaccination drive.
This is the second COVID-19 vaccine to get approved for children in India. DCGI had, in August, approved ZyCoV-D for children aged 12 and above as well as adults. However, the rollout has not yet begun.